Cannabis and Republican Party Politics: Evolution, Key Players & Policy Shifts

Executive Summary

The Republican Party's relationship with cannabis policy has undergone a dramatic transformation over the past decade, shifting from near-universal opposition to a complex patchwork of state-level support, federal reform advocacy, and strategic industry alignment. While the GOP platform historically championed prohibition and the War on Drugs, Republican-led states now account for more than half of all medical cannabis programs, and a growing faction of conservative lawmakers champions cannabis reform as a states' rights, criminal justice, and economic freedom issue. As of July 2026, major multi-state operators have redirected substantial lobbying resources toward Republican legislators, recognizing that durable federal reform requires bipartisan support. This shift reflects broader ideological tensions within conservatism: libertarian-leaning Republicans emphasize personal liberty and market opportunity, while social conservatives and law enforcement allies maintain traditional opposition. The cannabis industry's courtship of the GOP has accelerated since 2024, with trade groups now spending roughly equal amounts on Republican and Democratic campaigns, a stark reversal from the 90-10 Democratic tilt of 2018.

Why This Matters

Republican positioning on cannabis directly determines whether 38 million Americans in GOP-controlled states gain legal access, whether $30 billion in annual cannabis revenue remains state-siloed or enters interstate commerce, and whether the industry secures banking access and federal tax relief. The stakes span multiple constituencies. For patients, Republican governors and legislatures control medical cannabis access in states including Texas, Florida, Ohio, and Montana, affecting conditions from epilepsy to PTSD treatment for veterans. For operators, GOP support is essential for resolving the Section 280E tax burden that forces cannabis businesses to pay effective federal tax rates exceeding 70 percent, and for passing the SAFE Banking Act to end the cash-only operational model that invites theft and violence. For investors, Republican control of the House or Senate can make or break rescheduling timelines, uplisting to major exchanges, and institutional capital entry. State-level economics amplify the importance. Florida's medical program alone generated $2.1 billion in sales in 2025, with Republican leadership maintaining the framework while blocking adult-use expansion. Oklahoma's Republican-dominated legislature oversees one of the nation's most permissive medical markets, with over 2,800 dispensaries serving a population of 4 million. The partisan composition of state legislatures determines possession limits, cultivation rights, expungement pathways, and whether programs expand or contract. Federal policy remains the ultimate prize. Cannabis cannot cross state lines, access traditional banking, or deduct ordinary business expenses until Congress acts. Republicans held the House majority from 2023 to 2025 and regained Senate control in 2025, making GOP buy-in non-negotiable for any comprehensive reform. The Drug Enforcement Administration's proposed rescheduling from Schedule I to Schedule III, announced in May 2024, requires congressional acquiescence and faces Republican scrutiny over implementation details.

Background and History: From Nixon to the New GOP

The Republican Party's cannabis prohibition stance traces directly to President Richard Nixon's Controlled Substances Act of 1970 and the formal launch of the War on Drugs, which framed marijuana as a Schedule I narcotic with no accepted medical use and high abuse potential.

The Nixon and Reagan Era (1970-1992)

Nixon signed the Controlled Substances Act on October 27, 1970, codified at 21 U.S.C. § 801 et seq., establishing the five-schedule classification system. Despite the Shafer Commission's 1972 recommendation to decriminalize personal use, Nixon rejected the findings, and cannabis remained Schedule I alongside heroin and LSD. The Republican platform of 1972 made no mention of marijuana, but Nixon's public statements and the creation of the DEA in 1973 cemented enforcement as policy. President Ronald Reagan escalated prohibition dramatically. The 1984 Republican platform explicitly called for "strong enforcement of drug laws," and Reagan signed the Anti-Drug Abuse Act of 1986, which established mandatory minimum sentences and expanded asset forfeiture. First Lady Nancy Reagan's "Just Say No" campaign became cultural shorthand for zero-tolerance. Federal cannabis arrests increased 62 percent between 1982 and 1989, and the administration opposed state medical research programs in California and New Mexico. President George H.W. Bush continued the framework. His 1989 National Drug Control Strategy, delivered by drug czar William Bennett, requested $7.9 billion for interdiction and enforcement. The 1992 Republican platform stated: "We will continue the Bush Administration's strong enforcement of drug laws."

The Gingrich Congress and State Defiance (1994-2008)

The 1994 Republican Revolution brought Newt Gingrich to the House Speakership with a tough-on-crime mandate. Gingrich proposed the death penalty for drug smugglers carrying more than two ounces of marijuana, a position he later moderated. The 1996 Republican platform called for "a renewed commitment to the War on Drugs." California's Proposition 215, passed in November 1996, created the first modern medical cannabis program and forced a federal-state confrontation. The Clinton administration, with Republican congressional support, threatened to revoke DEA licenses of physicians who recommended cannabis. The Conant v. Walters litigation (eventually decided in 2003) established First Amendment protections for doctor-patient discussions, but Republican lawmakers largely opposed state programs. President George W. Bush maintained strict prohibition. His DEA conducted an average of 230 raids per year on state-legal dispensaries between 2001 and 2008, primarily in California. The 2004 and 2008 Republican platforms contained no softening language, and Bush's Office of National Drug Control Policy spent $1.4 billion on anti-drug advertising, much targeting marijuana.

The Tea Party and Libertarian Crosscurrents (2009-2016)

The Tea Party movement introduced ideological complexity. While focused on fiscal conservatism, the movement's states' rights emphasis created openings. Representative Ron Paul of Texas, a Republican presidential candidate in 2008 and 2012, explicitly called for ending federal cannabis prohibition, framing it as a Tenth Amendment issue. His son, Senator Rand Paul of Kentucky, co-sponsored the CARERS Act in 2015, the first major Republican-backed medical cannabis bill. Colorado and Washington legalized adult-use cannabis in November 2012, both states with Republican legislative minorities that included reform supporters. The 2012 Republican platform still stated: "We support a drug-free workplace," but cracks appeared. Representative Dana Rohrabacher of California, a Republican, co-sponsored the Rohrabacher-Farr Amendment in 2014, which prohibited the Department of Justice from using funds to interfere with state medical programs. The amendment passed with 49 Republican votes. Alaska and Oregon legalized adult use in 2014, followed by California, Maine, Massachusetts, and Nevada in 2016. Republican opposition remained the majority position, but state-level GOP officials in Alaska and Nevada declined to actively campaign against the measures, citing voter preference and revenue potential.

The Trump Administration Paradox (2017-2021)

President Donald Trump's position on cannabis was inconsistent, creating both hope and alarm. During the 2016 campaign, Trump stated he supported medical cannabis and believed recreational legalization should be a state decision. However, his appointment of Senator Jeff Sessions of Alabama as Attorney General signaled a hard-line approach. Sessions, who once said "good people don't smoke marijuana," rescinded the Obama-era Cole Memorandum on January 4, 2018, removing guidance that deprioritized federal enforcement in legal states. The rescission triggered backlash from Republican governors and legislators in legal states. Governor John Kasich of Ohio, Governor Charlie Baker of Massachusetts, and Senator Cory Gardner of Colorado all criticized the move. Gardner blocked DOJ nominees until Trump personally assured him Colorado would not face federal intervention, a promise Trump made in April 2018. The 2018 Farm Bill, signed by Trump on December 20, 2018, legalized hemp (cannabis with less than 0.3 percent THC) and was championed by Senate Majority Leader Mitch McConnell of Kentucky, a Republican who saw hemp as an economic opportunity for tobacco farmers. The bill marked the first time since 1937 that federal law distinguished between cannabis varieties, and it passed with overwhelming Republican support. Trump's 2020 budget proposed eliminating the Rohrabacher-Blumenauer protections for state medical programs, but Congress retained them. In his final year, Trump commuted the sentences of several non-violent cannabis offenders but did not pursue broader reform. The 2020 Republican platform was a one-page resolution reaffirming the 2016 platform, which contained no cannabis language.

The Biden Rescheduling and GOP Response (2021-2026)

President Joe Biden's October 2022 directive to review cannabis scheduling set in motion the most significant federal policy shift in 50 years. The Department of Health and Human Services recommended rescheduling to Schedule III in August 2023, and the DEA published a Notice of Proposed Rulemaking on May 21, 2024. The comment period closed in July 2024 with over 43,000 submissions, and an administrative law judge hearing is scheduled for December 2026. Republican reactions split along factional lines. Senator Rand Paul called rescheduling "a step in the right direction but insufficient," advocating for full descheduling. Representative Nancy Mace of South Carolina introduced the States Reform Act in November 2021, a comprehensive legalization bill that emphasized state control and small business access. Mace reintroduced the bill in 2023 and 2025, attracting co-sponsors including Representatives Matt Gaetz of Florida and Dave Joyce of Ohio. Conversely, Senator Tom Cotton of Arkansas and Representative Andy Biggs of Arizona led opposition, arguing that rescheduling would increase youth access and contradict international treaty obligations under the Single Convention on Narcotic Drugs of 1961. The Republican Study Committee, representing over 170 House conservatives, issued a 2024 budget proposal calling for "robust enforcement of federal drug laws." State-level Republican actions accelerated. Ohio voters approved adult-use legalization in November 2023, and the Republican-controlled legislature implemented the program despite initial resistance. Florida's Republican Governor Ron DeSantis opposed a 2024 adult-use ballot measure, which failed with 48 percent support, but maintained the state's $2 billion medical program. Montana's Republican legislature expanded its medical program in 2021 after voters approved adult use in 2020.

Key Players

Republican Legislators and Advocates

Representative Nancy Mace has emerged as the most prominent Republican reform champion, introducing comprehensive legalization legislation and framing cannabis as a criminal justice and economic issue. Her States Reform Act would remove cannabis from the Controlled Substances Act, impose a 3 percent federal excise tax, and allow states to maintain prohibition if they choose. Mace represents South Carolina's 1st District and has stated that her position reflects constituent support and recognition of failed prohibition. Senator Rand Paul has consistently advocated for ending federal prohibition since entering the Senate in 2011. He co-sponsored the CARERS Act, the STATES Act, and has called the War on Drugs "an abysmal failure." Paul frames cannabis reform as a federalism issue, arguing that the Tenth Amendment reserves drug policy to states. Representative Dave Joyce of Ohio co-chairs the Congressional Cannabis Caucus and has sponsored multiple bills, including the SAFE Banking Act and the GRAM Act, which would protect gun rights for cannabis users. Joyce's district includes significant medical cannabis cultivation, and he has stated that his position evolved after meeting patients and business owners. Governor Brian Kemp of Georgia signed a 2023 bill expanding the state's limited medical program to allow in-state cultivation, reversing his earlier opposition. Kemp cited patient access and economic development as reasons for the shift.

Republican Opposition Leaders

Senator Tom Cotton has been the most vocal Senate opponent, arguing that cannabis is a gateway drug and that legalization would increase impaired driving and youth use. Cotton represents Arkansas, which has a medical program approved by voters in 2016, but he has stated he would vote to repeal it if given the opportunity. Representative Andy Biggs chairs the House Freedom Caucus and has opposed all reform legislation, citing concerns about workplace safety and federal treaty obligations. Biggs represents Arizona, which legalized adult use in 2020, creating a disconnect between his position and state law. Smart Approaches to Marijuana (SAM), led by Kevin Sabet, is the primary opposition organization and has received funding from Republican donors. SAM opposes legalization and rescheduling, advocating instead for decriminalization with mandatory treatment. The group has testified before Republican-led committees and advised GOP legislators.

Industry and Trade Groups

The U.S. Cannabis Council, National Cannabis Industry Association, and American Trade Association for Cannabis and Hemp have all increased Republican outreach since 2022. According to Federal Election Commission data, cannabis industry PACs contributed $4.2 million to Republican candidates in the 2024 cycle, compared to $890,000 in 2020. Major MSOs including Curaleaf, Trulieve, and Green Thumb Industries have hired Republican lobbyists and former GOP staffers. The Cannabis Trade Federation, formed in 2019, explicitly targets Republican lawmakers and emphasizes free-market arguments. The group's board includes former Republican congressional staffers and has coordinated fly-ins with GOP offices.

Legal and Regulatory Framework

Cannabis remains a Schedule I controlled substance under the Controlled Substances Act, 21 U.S.C. § 812, meaning federal law classifies it as having no accepted medical use and high abuse potential, creating a direct conflict with 38 state medical programs and 24 adult-use programs. The Supremacy Clause of the U.S. Constitution, Article VI, Clause 2, establishes that federal law preempts conflicting state law. However, the anti-commandeering doctrine, established in Printz v. United States (1997) and reaffirmed in Murphy v. NCAA (2018), prevents the federal government from compelling states to enforce federal law. This creates the current equilibrium: states can legalize and regulate cannabis, but federal prohibition remains, and federal agencies can enforce it. The Rohrabacher-Blumenauer Amendment, renewed annually in appropriations bills since 2014, prohibits the Department of Justice from spending funds to prevent states from implementing medical cannabis laws. The provision does not protect adult-use programs and does not change the underlying Schedule I status. It has been renewed with bipartisan support, including Republican votes, in every Congress since 2014. Section 280E of the Internal Revenue Code, 26 U.S.C. § 280E, prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. Cannabis businesses can deduct cost of goods sold but not rent, salaries, marketing, or other expenses, resulting in effective tax rates of 70 to 90 percent. Rescheduling to Schedule III would eliminate 280E liability, providing an estimated $1.5 billion in annual tax relief to the industry. The SAFE Banking Act, first introduced in 2013 and passed by the House seven times, would prevent federal banking regulators from penalizing financial institutions that serve state-legal cannabis businesses. The bill has attracted Republican support, with 106 House Republicans voting for it in 2021, but has stalled in the Senate. Republican Senator Steve Daines of Montana is a co-sponsor, citing safety concerns from cash-only businesses. The proposed rescheduling to Schedule III, published in the Federal Register on May 21, 2024, follows the Administrative Procedure Act, 5 U.S.C. § 551 et seq. The DEA must consider public comments, hold a hearing before an administrative law judge, and issue a final rule. The process is expected to conclude in 2027, and any final rule can be challenged in federal court. Republican attorneys general from 15 states submitted comments opposing rescheduling, arguing it contradicts the text of the Controlled Substances Act and international treaties.

State-by-State Republican Positioning

Republican-controlled states account for 18 of 38 medical cannabis programs and 6 of 24 adult-use programs, with wide variation in possession limits, qualifying conditions, and regulatory structure.

Florida

Florida operates the nation's second-largest medical cannabis market, with $2.1 billion in sales in 2025. The program, approved by voters via Amendment 2 in 2016 with 71 percent support, allows patients with qualifying conditions including cancer, epilepsy, PTSD, and chronic pain to purchase up to 2.5 ounces every 35 days. The Republican-controlled legislature implemented the program in 2017 and has expanded qualifying conditions, but Governor Ron DeSantis opposed a 2024 adult-use ballot measure, which received 48 percent support and failed to reach the required 60 percent threshold. The state has 25 licensed operators, all vertically integrated, and over 800,000 active patients as of June 2026.

Ohio

Ohio voters approved adult-use legalization in November 2023 with 57 percent support, and the Republican-controlled legislature implemented the program in 2024 after initial attempts to block it. Adults 21 and older may possess up to 2.5 ounces and cultivate six plants at home. The state's medical program, launched in 2019, serves over 200,000 patients. Republican Governor Mike DeWine opposed the ballot measure but declined to interfere with implementation, stating that voters had spoken. The state collected $87 million in adult-use tax revenue in the first six months of 2026.

Montana

Montana voters approved adult-use legalization in November 2020 with 57 percent support, and the Republican legislature implemented the program in 2021. Adults may possess up to one ounce and cultivate four plants. The state's medical program, first approved in 2004, was nearly repealed by the Republican legislature in 2011 but was restored via ballot measure in 2016. Republican Governor Greg Gianforte signed the adult-use implementation bill, stating it reflected voter will and would generate revenue for conservation programs. Montana collected $43 million in cannabis tax revenue in 2025.

Alaska

Alaska legalized adult use in 2014 with 53 percent support, becoming the first red state to do so. The Republican-majority legislature implemented the program with minimal resistance, consistent with the state's libertarian culture. Adults may possess up to one ounce and cultivate six plants. The state's medical program, approved in 1998, allows patients to possess up to one ounce and cultivate six plants. Alaska collected $18 million in cannabis tax revenue in 2025.

Oklahoma

Oklahoma operates one of the nation's most permissive medical programs, approved by voters in 2018 with 57 percent support. The program has no specific list of qualifying conditions; any physician can recommend cannabis for any condition. The state has over 2,800 dispensaries and 376,000 active patients as of June 2026, representing nearly 10 percent of the population. The Republican-controlled legislature has attempted to impose stricter regulations, including residency requirements and possession limits, but has faced pushback from the industry and patients. The state collected $86 million in medical cannabis tax revenue in 2025.

Texas

Texas operates a highly restrictive medical program, the Compassionate Use Program, which allows patients with epilepsy, PTSD, cancer, and autism to access low-THC cannabis (up to 1 percent THC by weight). The program, established in 2015 and expanded in 2019 and 2021, has fewer than 50,000 registered patients as of June 2026. The Republican-controlled legislature has repeatedly rejected broader legalization, but a growing faction supports expansion. Representative Stephanie Klick, a Republican, has sponsored bills to add chronic pain and PTSD to qualifying conditions. Governor Greg Abbott has stated he would not support adult-use legalization but is open to medical expansion.

South Dakota

South Dakota voters approved both medical and adult-use cannabis in November 2020, but the state Supreme Court invalidated the adult-use measure on procedural grounds in 2021. The medical program launched in 2021, allowing patients with qualifying conditions to possess up to three ounces. Republican Governor Kristi Noem has been a vocal opponent, calling cannabis a "dangerous drug" and vetoing bills to expand the medical program. Advocates placed another adult-use measure on the 2022 ballot, which failed with 47 percent support. The state's medical program serves approximately 8,000 patients as of June 2026.

Utah

Utah voters approved a medical cannabis initiative in November 2018 with 53 percent support, but the Republican-controlled legislature replaced it with a more restrictive compromise before implementation. The program allows patients with qualifying conditions including cancer, HIV/AIDS, epilepsy, and PTSD to access cannabis in non-smokable forms. The state operates a unique central-fill pharmacy model, where the state contracts with a single cultivator and distributes through state-run pharmacies. The program serves approximately 35,000 patients as of June 2026. Republican Governor Spencer Cox has stated he personally opposes cannabis but respects the voter-approved program.

Market and Business Implications

Republican support for cannabis reform directly impacts whether the $30 billion U.S. cannabis market can access banking, eliminate the 280E tax burden, and enter interstate commerce, with MSO valuations hinging on federal policy changes. The Section 280E tax burden is the industry's most acute financial challenge. Because cannabis remains Schedule I, businesses cannot deduct rent, payroll, marketing, or other ordinary expenses under 26 U.S.C. § 280E. A typical dispensary with $5 million in revenue and $3 million in cost of goods sold might have $1.5 million in operating expenses, leaving $500,000 in pre-tax profit. Under normal tax treatment, the business would pay approximately $105,000 in federal tax (21 percent corporate rate). Under 280E, the business pays tax on $2 million ($5 million revenue minus $3 million COGS), resulting in a $420,000 tax bill—an effective rate of 84 percent on actual profit. Rescheduling to Schedule III would eliminate this burden, providing an estimated $1.5 billion in annual industry-wide tax relief. Republican support is essential for rescheduling to survive. The DEA's proposed rule faces a December 2026 administrative law judge hearing, and any final rule can be challenged in federal court. If Republicans control the House or Senate in 2027, they could use the Congressional Review Act, 5 U.S.C. § 801 et seq., to overturn the rule with a simple majority vote. Industry lobbyists have prioritized building Republican support to prevent this outcome. The SAFE Banking Act would allow financial institutions to serve cannabis businesses without fear of federal penalties. Currently, most banks refuse cannabis accounts due to concerns about Bank Secrecy Act violations and asset forfeiture under 18 U.S.C. § 1956 (money laundering). This forces businesses to operate in cash, increasing robbery risk and complicating tax compliance. The bill passed the House in 2021 with 106 Republican votes, but Senate Majority Leader Chuck Schumer declined to bring it to a vote, insisting on comprehensive reform. Republican Senator Steve Daines of Montana is a co-sponsor, and industry groups have focused on recruiting additional GOP senators. Interstate commerce remains prohibited under the Controlled Substances Act's Schedule I status. Each state operates a closed-loop system, with cultivation, processing, and retail confined within state borders. This prevents economies of scale and forces operators to build redundant infrastructure in each state. Rescheduling to Schedule III would not automatically permit interstate commerce—that would require congressional action—but it would remove the statutory barrier and allow the FDA to regulate cannabis as a pharmaceutical, potentially creating a pathway for interstate medical sales. Capital markets access depends on federal policy. U.S. cannabis companies cannot list on the New York Stock Exchange or Nasdaq due to federal illegality, forcing them to trade on the Canadian Securities Exchange or over-the-counter markets with limited liquidity. Institutional investors, including most pension funds and mutual funds, cannot invest due to compliance concerns. Rescheduling to Schedule III would likely trigger uplisting, as exchanges would no longer face federal trafficking concerns. This could unlock tens of billions in institutional capital. Republican positioning also affects M&A activity. Major alcohol, tobacco, and pharmaceutical companies have largely avoided U.S. cannabis investments due to federal illegality. Constellation Brands invested $4 billion in Canadian producer Canopy Growth in 2018, but has not entered the U.S. market. Altria invested $1.8 billion in Cronos Group, also Canadian. Republican support for rescheduling or legalization would likely trigger a wave of strategic investments and acquisitions, consolidating the fragmented U.S. market.

What Experts Say

Policy analysts, industry executives, and political strategists describe the Republican shift on cannabis as driven by state-level voter support, recognition of prohibition's failure, and economic opportunity, but tempered by social conservative resistance and law enforcement concerns. According to Morgan Fox, political director of the National Cannabis Industry Association, Republican engagement has increased substantially since 2020. Fox stated in a 2025 interview that the industry now receives meetings with Republican offices that previously refused contact, and that economic arguments resonate more than social justice framing. Fox noted that Republican legislators from legal states are significantly more supportive than those from prohibition states, suggesting that familiarity reduces opposition. Kevin Sabet, president of Smart Approaches to Marijuana and a former Obama administration drug policy advisor, argues that Republican support is shallow and driven by industry lobbying rather than constituent demand. Sabet has testified before Republican-led committees that legalization increases youth use, impaired driving, and workplace accidents, and that rescheduling contradicts the scientific evidence. SAM's polling, conducted in 2024, found that 62 percent of Republicans oppose adult-use legalization, though 71 percent support medical access. David Culver, senior vice president of government relations at Curaleaf, one of the nation's largest MSOs, described the Republican outreach strategy in a 2024 cannabis industry conference. Culver, a former Republican congressional staffer, said the industry emphasizes job creation, tax revenue, and small business opportunity when meeting with GOP offices, and avoids social justice language that can trigger resistance. Curaleaf has hired multiple Republican lobbyists and contributed to GOP campaigns in Florida, Arizona, and Ohio. According to Professor John Hudak of the Brookings Institution, who studies cannabis policy, the Republican Party is experiencing a generational divide. Hudak's research, published in 2023, found that Republicans under 40 support legalization at rates comparable to Democrats, while Republicans over 60 oppose it by margins of 2-to-1. Hudak predicts that demographic replacement will continue to erode opposition, but that the pace depends on whether older Republicans moderate their views or remain opposed. Sheriff Mark Lamb of Pinal County, Arizona, a Republican who ran for U.S. Senate in 2024, represents law enforcement skepticism. Lamb has stated that legalization has increased impaired driving arrests in Arizona and that the industry's tax revenue does not offset social costs. The National Sheriffs' Association, which includes many Republican sheriffs, opposes legalization and rescheduling, citing concerns about cartel activity and youth access.

What's Next

The DEA's administrative law judge hearing on rescheduling, scheduled for December 2026, represents the most significant near-term decision point, with Republican congressional and state responses determining whether the rule survives implementation. The hearing will consider public comments, scientific evidence, and statutory criteria under the Controlled Substances Act. The administrative law judge will issue a recommendation to the DEA Administrator, who will then issue a final rule. This process is expected to conclude in mid-2027. If the final rule reschedules cannabis to Schedule III, it will take effect 30 days after publication in the Federal Register unless Congress intervenes. The Congressional Review Act, 5 U.S.C. § 801, allows Congress to overturn agency rules with a simple majority vote in both chambers and presidential signature. If Republicans control the House or Senate in 2027 and oppose rescheduling, they could force a vote to block it. Industry lobbyists are working to ensure sufficient Republican support to prevent this outcome, targeting senators in legal states including Montana, Alaska, and Ohio. State-level Republican actions will continue to shape the landscape. Florida will likely see another adult-use ballot measure in 2026 or 2028, and polling suggests it could reach the 60 percent threshold if Republican opposition softens. Texas advocates are collecting signatures for a 2026 medical expansion initiative, which would bypass the legislature. South Dakota may see a third adult-use attempt in 2024 or 2026. The 2026 midterm elections will determine congressional control and committee leadership. If Republicans retake the House, Representative Nancy Mace could chair a subcommittee with cannabis jurisdiction, accelerating reform legislation. Conversely, if social conservatives gain influence, they could block floor votes on the SAFE Banking Act or other incremental bills. Presidential politics will also play a role. The 2028 Republican primary field will likely include candidates with varying cannabis positions. Governor Ron DeSantis has opposed adult use but maintained Florida's medical program. Former President Donald Trump's position remains ambiguous, but his 2024 campaign included rhetoric about pardoning non-violent drug offenders. A Republican presidential candidate who champions reform could shift party orthodoxy rapidly. International developments may create pressure. Canada legalized adult use in 2018, and Germany launched a limited adult-use program in 2024. If European countries continue to liberalize, Republican opponents will face questions about why the U.S. maintains prohibition while allies move forward.

Further Reading

• Controlled Substances Act, 21 U.S.C. § 801 et seq. — https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13.pdf
• DEA Notice of Proposed Rulemaking on Rescheduling, Federal Register Vol. 89, No. 100 (May 21, 2024) — https://www.federalregister.gov/documents/2024/05/21/2024-11137/schedules-of-controlled-substances-rescheduling-of-marijuana
• Congressional Research Service, "Marijuana: Medical and Retail—Selected Legal Issues" (updated 2024) — https://crsreports.congress.gov/product/pdf/R/R44782
• National Conference of State Legislatures, "State Medical Cannabis Laws" — https://www.ncsl.org/health/state-medical-cannabis-laws
• Federal Election Commission, Cannabis Industry Contributions Database — https://www.fec.gov/data/
• Brookings Institution, John Hudak, "Marijuana: A Short History" (2020) — https://www.brookings.edu/books/marijuana-a-short-history/
• U.S. Department of Health and Human Services, Recommendation to Reschedule Marijuana (August 2023) — https://www.hhs.gov/about/news/2023/08/30/hhs-recommends-rescheduling-marijuana.html
• Smart Approaches to Marijuana, Policy Positions and Research — https://learnaboutsam.org/
• Republican Party Platforms, 1972-2024 — https://www.presidency.ucsb.edu/documents/app-categories/elections-and-transitions/party-platforms
• Internal Revenue Code Section 280E, 26 U.S.C. § 280E — https://www.law.cornell.edu/uscode/text/26/280E